Perspective.
9 articles on perspective — analysis from the Asthra team and our advisor network.
2026
CBER updated the procedure your BLA has to survive. There is no redline.
SOPP 8401 governs what happens to an original BLA before the science gets its full review. Its effective date is now 29 July 2026. Sixteen of CBER's fifty-six published procedures carry a 2026 date in a year barely half over. There is no Federal Register notice, no docket, no comment period and no redline for any of them.
2026
FDA challenged two sponsors' efficacy cases. One panel agreed, one didn't.
On consecutive days in late July, FDA advisers voted 9-3 against Capricor's deramiocel and 10-3 that Replimune's IGNYTE results were evaluable and clinically meaningful. Both sponsors walked in behind an FDA briefing document that publicly challenged their efficacy case. The agency's document set the terms of both arguments. It decided neither.
2026
FDA showed you the safety lens its reviewers use. Your ISS may be using another one.
CDER posted two on-demand webinars in June with no announcement: one on the standard safety tables and figures guide, one on the 104 Office of New Drugs Custom Medical Queries used for safety signal detection. They aren't requirements. They are a description of what happens to your adverse event data after it arrives.
2026
Five sources moved in five weeks. That's a provenance problem.
A withdrawn guidance, an advisory committee whose charter lapsed, two retracted papers, a set of journal articles the agency has now disowned, and a rejection-letter programme that paused and restarted. Regulatory documents record what they depend on. They can't tell you what depends on them.
2026
FDA says CMC readiness is the bottleneck. The pilot built for it is running out of road.
On 23 July FDA published a strategy document naming CMC readiness as the thing that breaks on accelerated timelines. The same week it emerged that the pilot built for exactly that problem is winding down, undersubscribed, after three years. In the published rejection letters, 65% cite facility deficiencies and 51% cite CMC — against 26% for efficacy.
2026
The document was never the source of truth
Regulatory writing treats the Word file as the thing you trust — the artifact you edit, version, and pass around. It isn't. The document is a render of decisions, data, and provenance that live somewhere else, and once you take that seriously the whole tool changes shape.
2026
The expedited lane is now the default. This has an implication on regulatory drafting.
More than 70% of last year's new drugs took an expedited path, and most of this month's designations are Fast Track or Orphan. The compressed timeline lands on a part of the process nobody plans for — the drafting.
2026
FDA reversed its CRL pause in a week. That's not the part worth watching.
The FDA paused public release of Complete Response Letters, then posted 14 new ones days later. The policy will keep swinging. Meanwhile there were 455 rejection letters already in the public database when I checked, and almost no one drafting submissions is reading them.
2026
Solving hallucinations won't make an AI regulatory-writing tool work
Everyone asks whether the AI hallucinates, and assumes that if it doesn't, the product works. A regulated document is a big, coherent argument grounded in real data — and getting a tool to actually help write one takes more than accuracy.
See it on a real CSR, PSUR, or CER.
Asthra's five-step loop — Plan, Retrieve, Draft, Review & refine, Hand off — running on real regulatory documents, not slides.